Loading...
Loading...
EYEN| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 271.2K |
| Gross Profit | -271.2K |
| Operating Expense | 5,960.9K |
| Operating I/L | -5,960.9K |
| Other Income/Expense | -255.0K |
| Interest Income | 183.6K |
| Pretax | -6,215.9K |
| Income Tax Expense | 687.2K |
| Net Income/Loss | -6,215.9K |
Eyenovia, Inc. is a clinical stage ophthalmic company specializing in developing therapeutics using its proprietary microdose array print platform technology. The company's focus is on developing clinical microdosing of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. Its product candidates include MicroLine for near vision improvement in people with presbyopia, MicroPine for pediatric myopia progression, and MydCombi for pharmaceutical mydriasis. Eyenovia has license agreements with Bausch Health Ireland Limited and Arctic Vision (Hong Kong) Limited for the development and commercialization of its products in various regions.
